Russia Venture Fund, AstraZeneca Sign MOU To Develop Targeted Drugs
This article was originally published in PharmAsia News
Executive Summary
A Russian venture fund has signed a memorandum of understanding with AstraZeneca PLC to cooperate in creating an infrastructure for developing personalized drugs.